Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Moss

Showing results (251-260 of 308) with videos related to

Pageof 31
Sort By:
Journal of Virology|July 3, 2015
Salmon Gill Poxvirus, the Deepest Representative of the ChordopoxvirinaeMona C Gjessing, Natalya Yutin, Torstein Tengs, et al.
Journal of Virology|November 6, 2007
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of DryvaxD Huw Davies, Linda S Wyatt, Frances K Newman, et al.
Vaccine|August 6, 2009
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccinesPatricia L Earl, Catherine Cotter, Bernard Moss, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2023
Human FAM111A inhibits vaccinia virus replication by degrading viral protein I3 and is antagonized by poxvirus host range factor SPI-1Junda Zhu, Xintao Gao, Yijing Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2007
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in miceAndreas Bråve, Andreas Boberg, Lindvi Gudmundsdotter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 16, 2010
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccineSunil Kannanganat, Pragati Nigam, Vijayakumar Velu, et al.
Virology|May 16, 2002
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque modelPatricia L Earl, Linda S Wyatt, David C Montefiori, et al.
The Journal of Infectious Diseases|June 2, 2011
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccineLilin Lai, Suefen Kwa, Pamela A Kozlowski, et al.
Journal of Virology|June 22, 2007
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection modelZhaochun Chen, Patricia Earl, Jeffrey Americo, et al.
Virology|May 15, 2007
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primatePatricia L Earl, Jeffrey L Americo, Linda S Wyatt, et al.
Pageof 31

Showing results (251-260 of 308) with videos related to

Sort By:
Pageof 31
Journal of Virology|July 3, 2015
Salmon Gill Poxvirus, the Deepest Representative of the ChordopoxvirinaeMona C Gjessing, Natalya Yutin, Torstein Tengs, et al.
Journal of Virology|November 6, 2007
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of DryvaxD Huw Davies, Linda S Wyatt, Frances K Newman, et al.
Vaccine|August 6, 2009
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccinesPatricia L Earl, Catherine Cotter, Bernard Moss, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2023
Human FAM111A inhibits vaccinia virus replication by degrading viral protein I3 and is antagonized by poxvirus host range factor SPI-1Junda Zhu, Xintao Gao, Yijing Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2007
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in miceAndreas Bråve, Andreas Boberg, Lindvi Gudmundsdotter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 16, 2010
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccineSunil Kannanganat, Pragati Nigam, Vijayakumar Velu, et al.
Virology|May 16, 2002
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque modelPatricia L Earl, Linda S Wyatt, David C Montefiori, et al.
The Journal of Infectious Diseases|June 2, 2011
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccineLilin Lai, Suefen Kwa, Pamela A Kozlowski, et al.
Journal of Virology|June 22, 2007
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection modelZhaochun Chen, Patricia Earl, Jeffrey Americo, et al.
Virology|May 15, 2007
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primatePatricia L Earl, Jeffrey L Americo, Linda S Wyatt, et al.
Pageof 31